ResearchAndMarkets.com s offering.
This report highlights the current and future market potential for softgel capsules and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, and trends in the market. The report also covers market projections through 2025, as well as key market players.
This report details market shares for softgel capsules based on application, end-user and geography. Based on application, the market is segmented into health supplements, vitamins and dietary supplements, and others. Based on end-user, the market is segmented into pharmaceutical and nutraceutical companies, contract manufacturing companies, and others.
Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional
Press release content from Business Wire. The AP news staff was not involved in its creation.
Insights on the Softgel Capsules Global Market to 2025 - Impact Analysis of COVID-19 - ResearchAndMarkets.com
February 11, 2021 GMT
The “Softgel Capsules: Global Markets” report has been added to ResearchAndMarkets.com’s offering.
This report highlights the current and future market potential for softgel capsules and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, and trends in the market. The report also covers market projections through 2025, as well as key market players.
ADVERTISEMENT
This report details market shares for softgel capsules based on application, end-user and geography. Based on application, the market is segmented into health supplements, vitamins and dietary supplements, and others. Based on end-user, the market is segmented into pharmaceutical and nutraceutical companies, contract manufactu
Strides reports 34 pc revenue and 76 pc EBITDA growth YoY in Q3
Bengaluru, Feb 4 (UNI) Bengaluru headquartered global pharmaceutical company Strides Pharma Science Ltd has registered 34 percent revenue and 76 percent EBITDA growth in the Q3 FY21 and Nine months ended December 31, 2020 (9MFY21)
Dr R Ananthanarayanan, Managing Director & CEO, commenting on the performance, said, We are pleased to report steady performance of our businesses in Q3FY21. Our portfolio maximisation strategy is yielding the desired results and we continue to invest in R&D to expand our product offering across regulated markets. Our US strategy of building the front end and tapering the partner business is playing out to plan and our frontend now contributes ~86% of our US revenues . We are pleased to have received the USFDA approval for the gTRUVADA. During the quarter, we have successfully commercialized TLD from our institutional portfolio, he said.